Semaglutide
Guangzhou Pengjiao Biotechnology Pharmaceutical Co., Ltd. is an innovative pharmaceutical company focused on the treatment of obesity and weight management. The company is dedicated to providing safe and effective solutions for the global overweight and obese population through cutting-edge technology and precision medicine. It possesses an international R&D team, a GMP-compliant production base, and a global sales network covering major markets. Guided by the mission of "Scientific Weight Loss, Reshaping Healthy Life", the company drives innovation and breakthroughs in the field of obesity treatment.
Core products include long-acting injectables of GLP-1 receptor agonists, oral small-molecule dual-target inhibitors, and combination formulations targeting metabolic syndrome.
Collaborating with smart hardware (such as wearable metabolic monitoring devices) and AI algorithms, the company provides personalized weight loss plans encompassing dietary guidance, exercise planning, drug intervention, and psychological support.
The company partners with top domestic and international medical institutions to conduct multi-center clinical trials, validating the safety and efficacy of its products.